Pyrilinks-D assay

Pyrilinks®-D assay

Osteoporosis An immunoassay that measures deoxypyridinoline–Dpd crosslinks in urine, which are ↑ in osteoporosis. See Deoxypyridinoline.
References in periodicals archive ?
25-29) Pyrilinks-D assay has demonstrated precision and accuracy equal or superior to NTx and linear C telopeptides of type I collagen (CTx).
Saliva laboratory testing
In combination with Metra's own medical education efforts, the recent launch of our Pyrilinksr-D technology on Chiron Diagnostics' automated immunoassay system and the ongoing development of an in-office Pyrilinks-D assay that will be CLIA-waived, this program advances Metra further toward the goal of broad market awareness and demand for our products.
Norland Medical Systems, Metra Biosystems and Berlex Laboratories launch innovative co-promotion collaboration
The US Food and Drug Administration (FDA) has cleared the Pyrilinks-D assay for use as an indicator of bone loss (resorption).
The Pyrilinks-D assay allows physicians to `see' an individual's bone turnover rate and identifies which of their patients may be at risk for increased bone loss," said George W.
METRA BIOSYSTEMS ANNOUNCES FREE PYRILINKS(R)-D TESTING PROGRAM
The Pyrilinks-D assay received market clearance from the U.
The new Pyrilinks-D assay cassette would be the first cassette developed for the Cholestech L-D-X System to use a specimen other than blood and will utilize immunoassay based technology.
Cholestech Corporation Announces Agreement With Metra Biosystems on Bone Resorption
Under the terms of the agreement, Cholestech will be responsible for developing an immunoassay cassette incorporating the Pyrilinks-D assay and obtaining all regulatory clearances prior to marketing.
METRA BIOSYSTEMS ANNOUNCES PARTNERSHIP TO DEVELOP POINT-OF-CARE SYSTEM FOR BONE RESORPTION; Cholestech Corp. will use Proprietary Technology to Develop In-Office Urine-Based Pyrilinks-D Test
On January 2, Metra announced receipt of regulatory clearance for its Pyrilinks-D assay as an indicator of bone resorption (loss).
METRA BIOSYSTEMS, INC. REPORTS SECOND QUARTER 1996 RESULTS
Results suggest that combination of the Pyrilinks-D assay with ultrasonic bone mineral density measurements can provide an accurate tool in screening for patients with accelerated bone loss.
Current research strongly suggests that the Pyrilinks-D assay can be used to increase sensitivity and specificity of potential future mass screening efforts.
OSTEOPENIA DETECTION INCREASED WHEN PYRILINKS IS COMBINED WITH ULTRA-SOUND BONE MASS ASSESSMENT; Study Evaluates Combined Tests' Potential for Use in Mass Screening
Levels of free deoxypyridinoline (free-Dpyr) measured using Metra's Pyrilinks-D assay were higher in patients who experienced a hip fracture than age-matched controls by a statistically significant amount.
We are very excited that the results from this study suggest our Pyrilinks-D assay can help predict which patients may be at increased risk for hip fracture," said George W.
ADVANCE/Metra Assay Demonstrates Predictive Value for Hip Fractures; Biochemical Marker May Be Used to Determine Elderly Women at Increased Risk for Hip Fracture
Medical browser ?
Full browser ?